Nutra Pharma Corp.
Bringing Healthcare Solutions to the World
 
Drug Discovery
Overview
Conditions
Intellectual Property
Research
R&D Pipeline
Cobroxin
Drug Development
R&D Pipeline
Nutra Pharma is developing an innovative pipeline of biopharmaceutical products
E-Alerts
Signup to receive news and announcements from Nutra Pharma:
First Name:
Last Name:
Email:
Infinite Menus, Copyright 2006, OpenCube Inc. All Rights Reserved.

Research

Cobratoxin inhibits pain-evoked discharge of neurons in thalamic parafascicular nucleus in rats: Involvement of cholinergic and serotonergic systems

Toxicon

Volume 54/ Issue 4 (15 September 2009)

 

Alpha cobratoxin as a Possible Therapy for Multiple Sclerosis: A Review of the Literature leading to Its Development for This Application

Critical Reviews™ in Immunology
Volume 27/ Issue 4 2007

 

Analgesic effects of receptin, a chemically modified cobratoxin from Thailand cobra venom

Neuroscience Bulletin
September 2006

 

Amelioration of acute and relapsing stages of the Experimental Allergic Encephalomyelitis by Cobra Toxins

Biomedical Sciences Instrumentation
June 2006

 

A long-form a-neurotoxin from cobra venom produces potent opioid-independent analgesia

Acta Pharmacologica Sinica
April 2006

 

A short-chain a-neurotoxin from Naja naja atra produces potent cholinergic-dependent analgesia

Neuroscience Bulletin
March 2006

 
Quick Nav
Nyloxin // Chronic Pain Relief
Read about Jeff Gottfurcht, the first rheumatoid arthritis sufferer to conquer Everest, in Musculoskeletal Health a special section of the Washington Post.
 

 

 
Recent News
 
July 15, 2015
Nutra Pharma Announces the Submission of Their First Orphan Drug Application to the US Food and Drug Administration (FDA)


July 10, 2015
SeeThruEquity Initiates Coverage on Nutra Pharma Corporation with a Price Target of $0.53


June 30, 2015
Nutra Pharma Announces Engagement of Investment Banking Firm Pickwick Capital Partners to Provide Strategic Advisory Services


 
 
Announcements
Click here to view a Letter to Shareholders from the Company's CEO, Rik J Deitsch.
 
 
Facebook   Twitter
 
NPC
Privacy Policy Code of Ethics